Industry partnerships are crucial for more than just funding. Collaborating with pharmaceutical companies provides translation-focused questions that guide the design of advanced cell models, ensuring they are predictive, scalable, and compatible with real-world development workflows.

Voyager CEO Al Sandrock views partnerships as more than just revenue. He emphasizes that strong scientific collaborations are invaluable because direct interaction between partner scientists accelerates learning and overall progress for both organizations. This intellectual cross-pollination is a key, often overlooked, benefit of partnering out platform technology.

By open-sourcing its model, Boltz created a feedback loop where the community discovered novel use-cases, like a crude but effective "inference-time search" for antibody prediction. This demonstrates how open access allows external users to find creative applications the original developers hadn't considered.

Scientific progress requires more than just papers that lead to tenure. It also needs tool-building, software development, and connecting disparate ideas. These activities are valuable for science but often undervalued by academic incentive structures, creating an opportunity for new institutions to fill the gap.

Future progress in biology requires moving beyond static models. The new paradigm involves an AI that reasons over hypotheses, prioritizes experiments, learns from the empirical outcomes, and updates its internal world model. This creates a scalable, closed-loop system for scientific discovery.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

The prevailing biotech model is shifting from an asset-centric approach to one focused on creating a "learning system." The most successful future companies will be those with a repeatable engine for discovery and validation that can consistently generate new insights and a diversified pipeline of assets.

Michael Antonov argues against a pure AI approach. He envisions a future where hundreds of different models—statistical AI, precise molecular dynamics, and scalable coarse-grained models—are stacked together to simulate biological processes at different scales, bridging their individual gaps.

Antonov highlights a core conflict: VCs want tangible drug assets for monetization, but solving complex problems like aging requires building broad computational platforms. This focus on near-term assets starves the development of fundamental, long-term biological models.